Manufacturing & Packaging

In today’s Pharma Pulse, Novartis expands its US radioligand footprint, and 15,000 New York City nurses go on strike.

The pharma giant will invest in a 35,000-square-foot RLT manufacturing site in Winter Park, FL as part of its $23 billion US infrastructure expansion.

In the third part of his Pharma Commerce video interview, Franco Stevanato, CEO of Stevanato Group, shares how automatic contract adjustments tied to labor, energy, and inflation—combined with the critical role of supply reliability—allow the company to pass through limited surcharges while maintaining strong client relationships.

In today’s Pharma Pulse, Amazon Pharmacy launches Novo's first oral Wegovy pill with transparent cash pricing, Johnson & Johnson triples down on North Carolina manufacturing, and new clinical data links medical debt to rising eviction risks.

In the second part of his Pharma Commerce video interview, Franco Stevanato, CEO of Stevanato Group, describes how from FDA validation to dual-site redundancy and reshoring momentum, the expansion of US capacity is a competitive advantage for pharma clients navigating increasingly complex global supply chains.

In today’s Pharma Pulse, Johnson & Johnson secures a major tariff deal by joining the federal drug discount portal, while new data warns that missing early infant shots is the leading predictor of skipped MMR vaccines.

The pharma giant becomes the latest manufacturer to participate in the Trump Administration’s direct-to-patient pricing platform, aligning US drug costs with European benchmarks while reinforcing its domestic manufacturing investments.

In the first part of his Pharma Commerce video interview, Franco Stevanato, CEO of Stevanato Group, explains how near-term tariff pressures are creating short-term headwinds while accelerating longer-term investment in regional manufacturing footprints—especially in the US.

A new Foreign Trade Zone–enabled facility in Annville strengthens the company’s temperature-controlled, compliant logistics capabilities, while accelerating customs processing and last-mile healthcare delivery.

Merck’s decision to shutter its Riverside, PA antibiotic API facility underscores how decades of cost-driven optimization have eroded domestic manufacturing of essential medicines—exposing systemic vulnerabilities in US drug supply resilience that markets alone are unlikely to fix.

The sustainable packaging company relocates its branded foam production to a more expansive Lansing site, boosting capacity, efficiency, and support for growing demand in the life science market.

In the final part of her Pharma Commerce video interview, Tina Martinez, vice president and head of global products and solutions at Cencora, explains how streamlining clinical supply services, reducing fragmentation, and piloting data-driven tools like real-time adherence tracking are translating innovation into quantifiable efficiency, visibility, and commercial impact for manufacturers worldwide.

The South Korea–based CDMO acquires its first US manufacturing facility in Rockville, MD, expanding its global footprint and strengthening biologics capacity.

The CDMO’s latest GMP-qualified line strengthens sterile manufacturing scalability.

The pharmaceutical giant’s new 700,000-square-foot hub aims to onshore production of key medicines and strengthen the US drug supply chain.

CoverMyMeds’ Megan Wetzel unpacks the forces behind rising specialty spend, the real impact of access barriers, and how field reimbursement teams help providers guide patients through today’s fragmented system.

AI-powered control towers and digital twins are emerging as essential tools to prevent costly supply chain failures and restore operational reliability.

The entrepreneur urges the Trump administration to eliminate costly FDA generic drug fees, part of a broader push to scale domestic production, address shortages, and challenge PBM-driven pricing models.

The agreement includes exemptions for UK-produced drugs and medical devices from Section 232 tariffs, but mandates a significant change to the UK's NICE value appraisal framework.

The pharmaceutical giant will be nearly doubling biologics production in Frederick and build a new clinical supply facility in Gaithersburg, projects that will create thousands of jobs, enhance US supply chain resilience, and advance its growing rare disease portfolio.

In the fourth part of her Pharma Commerce video interview, Christy Christian, senior industry principal with Kinaxis, shares how reducing inefficiencies cuts waste, preserves profitability, and ultimately lowers consumer prices while increasing production capacity to meet rising demand.

The pharma giant’s new 10,000-square-foot Carlsbad plant strengthens its US manufacturing network and supports its overarching $50 billion investment plan committed to operations.

In the first part of her Pharma Commerce video interview, Christy Christian, senior industry principal with Kinaxis, describes how manufacturers face mounting challenges managing long, complex supply chains, including limited inventory buffers, tight cash flow constraints, and constant policy changes.

The investment is aimed at boosting oral medicine manufacturing capacity.

The move adds new tension to US-Canada trade relations under the USMCA and raises questions about pending pharmaceutical import policies.